A detailed history of Fayez Sarofim & CO transactions in Eli Lilly & CO stock. As of the latest transaction made, Fayez Sarofim & CO holds 367,875 shares of LLY stock, worth $293 Million. This represents 0.84% of its overall portfolio holdings.

Number of Shares
367,875
Previous 331,739 10.89%
Holding current value
$293 Million
Previous $300 Million 8.51%
% of portfolio
0.84%
Previous 0.82%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$772.14 - $960.02 $27.9 Million - $34.7 Million
36,136 Added 10.89%
367,875 $326 Million
Q2 2024

Aug 14, 2024

BUY
$724.87 - $909.04 $18.3 Million - $23 Million
25,270 Added 8.25%
331,739 $300 Million
Q1 2024

May 14, 2024

BUY
$592.2 - $792.28 $634,838 - $849,324
1,072 Added 0.35%
306,469 $238 Million
Q4 2023

Feb 14, 2024

BUY
$525.19 - $619.13 $19 Million - $22.4 Million
36,242 Added 13.47%
305,397 $178 Million
Q3 2023

Nov 14, 2023

BUY
$434.7 - $599.3 $15.6 Million - $21.6 Million
35,968 Added 15.42%
269,155 $145 Million
Q2 2023

Aug 14, 2023

BUY
$350.74 - $468.98 $11.9 Million - $15.9 Million
33,909 Added 17.02%
233,187 $109 Million
Q1 2023

May 11, 2023

BUY
$310.63 - $364.82 $16.9 Million - $19.8 Million
54,326 Added 37.48%
199,278 $68.4 Million
Q4 2022

Feb 13, 2023

BUY
$321.55 - $374.67 $35.5 Million - $41.4 Million
110,467 Added 320.33%
144,952 $53 Million
Q3 2022

Nov 14, 2022

BUY
$296.48 - $337.87 $126,004 - $143,594
425 Added 1.25%
34,485 $11.2 Million
Q2 2022

Aug 12, 2022

BUY
$278.73 - $327.27 $331,688 - $389,451
1,190 Added 3.62%
34,060 $11 Million
Q1 2022

May 16, 2022

BUY
$234.69 - $291.66 $269,424 - $334,825
1,148 Added 3.62%
32,870 $9.41 Million
Q4 2021

Feb 11, 2022

BUY
$224.85 - $279.04 $517,379 - $642,071
2,301 Added 7.82%
31,722 $8.76 Million
Q3 2021

Nov 15, 2021

SELL
$221.6 - $272.71 $34,569 - $42,542
-156 Reduced 0.53%
29,421 $6.8 Million
Q2 2021

Aug 13, 2021

BUY
$180.55 - $233.54 $341,961 - $442,324
1,894 Added 6.84%
29,577 $6.79 Million
Q1 2021

May 13, 2021

SELL
$164.32 - $212.72 $685,871 - $887,893
-4,174 Reduced 13.1%
27,683 $5.17 Million
Q4 2020

Feb 11, 2021

SELL
$130.46 - $172.63 $99,801 - $132,061
-765 Reduced 2.35%
31,857 $5.38 Million
Q3 2020

Nov 13, 2020

BUY
$146.22 - $169.13 $984,060 - $1.14 Million
6,730 Added 25.99%
32,622 $4.83 Million
Q2 2020

Aug 11, 2020

SELL
$136.42 - $164.18 $1.97 Million - $2.38 Million
-14,466 Reduced 35.84%
25,892 $4.25 Million
Q1 2020

May 12, 2020

BUY
$119.05 - $147.35 $45,953 - $56,877
386 Added 0.97%
40,358 $5.6 Million
Q4 2019

Feb 14, 2020

BUY
$106.92 - $132.43 $2.51 Million - $3.11 Million
23,450 Added 141.93%
39,972 $5.25 Million
Q3 2019

Nov 13, 2019

BUY
$106.79 - $116.16 $4,805 - $5,227
45 Added 0.27%
16,522 $1.85 Million
Q2 2019

Aug 09, 2019

SELL
$110.79 - $129.32 $6.6 Million - $7.71 Million
-59,606 Reduced 78.34%
16,477 $1.83 Million
Q1 2019

May 14, 2019

BUY
$111.31 - $131.02 $6.75 Million - $7.95 Million
60,686 Added 394.14%
76,083 $9.87 Million
Q4 2018

Feb 13, 2019

BUY
$105.9 - $118.64 $64,599 - $72,370
610 Added 4.13%
15,397 $1.78 Million
Q3 2018

Nov 14, 2018

BUY
$85.86 - $107.31 $42,930 - $53,655
500 Added 3.5%
14,787 $1.59 Million
Q2 2018

Aug 14, 2018

SELL
$75.7 - $86.88 $207,115 - $237,703
-2,736 Reduced 16.07%
14,287 $1.22 Million
Q1 2018

May 10, 2018

BUY
$74.21 - $87.6 $48,236 - $56,939
650 Added 3.97%
17,023 $1.32 Million
Q4 2017

Feb 13, 2018

SELL
$81.94 - $87.89 $1,147 - $1,230
-14 Reduced 0.09%
16,373 $1.38 Million
Q3 2017

Nov 08, 2017

BUY
$77.07 - $85.54 $1.26 Million - $1.4 Million
16,387
16,387 $1.4 Million

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $756B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Fayez Sarofim & CO Portfolio

Follow Fayez Sarofim & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fayez Sarofim & CO, based on Form 13F filings with the SEC.

News

Stay updated on Fayez Sarofim & CO with notifications on news.